Ten-year risk for coronary events according to different risk equations
| Equation scores | Mean ± SD | Number (%) | ||
|---|---|---|---|---|
| Low | Intermediate | High | ||
| FRS | ||||
| Without attributable risk of psoriasis | 5.8 ± 6.9 | 109 (75) | 30 (21) | 6 (4) |
| With attributable risk of psoriasis | 7.9 ± 7.3 | 97 (67) | 38 (26) | 10 (7) |
| RAMA-EGAT | 5.5 ± 5.1 | 126 (87) | 17 (12) | 2 (1) |
Logistic regression model to assess predictive factors that contribute to risk at ≥10% of coronary events as predicted by Ramathibodi–Electricity Generating Authority of Thailand (RAMA-EGAT) score
| Variables | RAMA-EGAT score | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| <10% risk (n = 126) | ≥10% risk (n = 19) | P | OR (95% CI) | P | OR (95% CI) | ||
| Duration of disease in years, mean ± SD | 12.5 ± 9.0 | 18.1 ± 9 . 7 | 0.02 | 1.06 (1.01,1.12) | 0.02 | 1.08 (1.01, 1.14) | |
| Severity Only 142 and 134 patients were available for the data regarding severity and obesity, respectively, OR = odds ratio, 95% CI = 95% confidence interval, SD = standard deviation | |||||||
| PASI <10 | 76 (62) | 16 (84) | 0.07 | 1 | 0.12 | 0.33 (0.08, 1.34) | |
| PASI ≥ 10 | 47 (38) | 3 (16) | 0.30 (0.08,1.10) | ||||
| Psoriatic arthritis, n (%) | |||||||
| No | 108 (86) | 14 (74) | 0.19 | 1 | 0.48 | 1.64 (0.42, 6.39) | |
| Yes | 18 (14) | 5 (26) | 2.14 (0.69,6.68) | ||||
| Treatment, n (%) | |||||||
| Topical | 42 (33) | 10 (53) | 0.11 | 1 | 0.02 | ||
| Systemic | 84 (67) | 9 (47) | 2.22 (0.84,5.88) | 3.95 (1.23, 12.68) | |||
| Obesity Only 142 and 134 patients were available for the data regarding severity and obesity, respectively, OR = odds ratio, 95% CI = 95% confidence interval, SD = standard deviation | |||||||
| No | 50 (43) | 5 (28) | 0.23 | 1 | 0.19 | 2.22 (0.67, 7.34) | |
| Yes | 66 (57) | 13 (72) | 1.97 (0.66,5.89) | ||||
Demographic data of Thai patients with psoriasis (n = 145)
| Demographic data | Mean ± SD or n (%) |
|---|---|
| Age (years) | 48.1 ± 14.1 |
| Age of onset (years) | 34.9 ± 14.0 |
| Duration of psoriasis (years) | 13.2 ± 9.2 |
| Sex | |
| Male | 72 (50) |
| Female | 73 (50) |
| Type of psoriasis by age of onset | |
| Type I (≤40 years) | 101 (70) |
| Type II (>40 years) | 44 (30) |
| Clinical type of psoriasis | |
| Plaque-type psoriasis | 133 (92) |
| Guttate psoriasis | 5 (3) |
| Psoriasis erythroderma | 4 (3) |
| Pustular psoriasis | 3 (2) |
| Number of patients who had psoriatic arthritis | 23 (16) |
| Disease severity (n = 142) | |
| PASI <10 | 92 (65) |
| PASI ≥10 | 50 (35) |
| Family history of psoriasis | 26 (18) |
| Treatment of psoriasis | |
| Topical therapy alone | 52 (36) |
| Systemic therapy | 93 (64) |
| Underlying diseases | |
| Obesity(BMI ≥25 kg/m2) | 79 (59) |
| Hypertension | 58 (40) |
| Dyslipidemia | 27 (19) |
| Diabetes mellitus | 23 (16) |
| Nonalcoholic fatty liver | 7 (5) |
| HIV infection | 4 (3) |
| BMI (kg/m2) | 26.6 ± 6.4 |
| Waist circumference >90 cm | 82 (43) |
| Fasting blood sugar level (mg/dL) | 105.8 ± 23.8 |
| Total cholesterol level (mg/dL) | 198.3 ± 37.3 |
| HDL cholesterol level (mg/dL) | 51.5 ± 14.0 |
| Current smoking | 23 (16) |
Logistic regression model to assess predictive factors that contribute to risk at ≥10% of coronary events as predicted by Framingham Risk Score
| Variables | FRS | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| <10% risk (n = 109) | ≥10% risk (n = 36) | P | OR (95% CI) | P | OR (95% CI) | |
| Duration of disease in years, mean ± SD | 11.9 ± 8.3 | 17.1 ± 10.7 | <0.001 | 1.14 (1.02, 1.11) | 0.001 | 1.09 (1.04,1.14) |
| Severity Only 142 and 134 patients were available for the data regarding severity and obesity, respectively, OR = odds ratio 95% CI = 95% confidence interval, SD = standard deviation, FRS = Framingham Risk Score, PASI = Psoriasis Area and Severity Index | ||||||
| PASI <10 | 64 (59) | 28 (78) | 0.06 | 1 | ||
| PASI ≥10 | 42 (39) | 8 (22) | 0.44 (0.18, 1.05) | |||
| Psoriatic arthritis, n (%) | ||||||
| No | 94 (86) | 28 (78) | 0.23 | 1 | ||
| Yes | 15 (14) | 8 (22) | 1.79 (0.69, 4.66) | |||
| Treatment, n (%) | 0.005 | 0.002 | ||||
| Topical | 32 (29) | 20 (56) | 31.03 (1.39, 6.54) | 4.63 (1.78, 12.05) | ||
| Systemic | 77 (71) | 16 (44) | 1 | |||
| Obesity Only 142 and 134 patients were available for the data regarding severity and obesity, respectively, OR = odds ratio 95% CI = 95% confidence interval, SD = standard deviation, FRS = Framingham Risk Score, PASI = Psoriasis Area and Severity Index | ||||||
| No | 55 (51) | 24 (67) | 0.07 | 1 | 0.04 | |
| Yes | 46 (42) | 9 (25) | 2.23 (0.94, 5.27) | 2.88 (1.08, 7.68) | ||
| Diabetes mellitus, n (%) | ||||||
| No | 95 (87) | 27 (75) | 0.09 | 1 | 0.21 | 1.99 (0.68, 5.75) |
| Yes | 14 (13) | 9 (25) | 2.26 (0.88, 5.79) | |||